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Abstract 
Critical limb ischemia (CLI), foot ulcers, former amputation and impaired regeneration are 
independent risk factors for limb amputation in diabetic subjects. The present work 
investigates whether and by which mechanism diabetes negatively impacts on functional 
properties of muscular pericytes (MPs), which are resident stem cells committed to reparative 
angiomyogenesis. 
We obtained muscle biopsies from diabetic patients undergoing major limb 
amputation and control subjects. Diabetic muscles collected at the rim of normal tissue 
surrounding the plane of dissection showed myofibres degeneration, fat deposition, and 
reduction of MPs vascular coverage. Diabetic MPs (D-MPs) display ultrastructural 
alterations, a differentiation bias towards adipogenesis at the detriment of myogenesis and an 
inhibitory activity on angiogenesis. Furthermore, they have an imbalanced redox state, with 
down-regulation of the anti-oxidant enzymes SOD-1 and catalase and activation of the pro-
oxidant PKCβII-dependent p66Shc signaling pathway. A reactive oxygen species scavenger 
or, even more effectively, clinically-approved PKCβII inhibitors restore D-MPs 
angiomyogenic activity. 
Inhibition of the PKCβII-dependent p66Shc signaling pathway could represent a novel 
therapeutic approach for promotion of muscle repair in diabetes. 
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Critical limb ischemia (CLI) represents the most severe manifestation of peripheral arterial 
disease (PAD) and the major cause of foot amputation in the United States (1). Most 
amputations are carried out on people with diabetes mellitus, who have rampant 
atherosclerosis and poor angiomyogenesis (2-5).  
Satellite cells and pericytes, which reside on opposite sides of the myofibres basement 
membrane, represent the main myogenic stem/progenitor cells in the postnatal skeletal 
muscle (6). Satellite cells are well acknowledged targets of diabetes-induced damage and 
contributors of diabetic vascular myopathy (7-10). Recent evidence indicates pericytes play 
key role in vascular and muscular regeneration (11-13) and have potential to become favorite 
candidates for cell therapy of PAD and myocardial ischemia (14-17). However, to the best of 
our knowledge, no investigation has assessed the impact of diabetes on the functional and 
molecular makeup of muscular pericytes (MPs).  
The mitochondrial adaptor protein Shc1, isoform p66 (p66Shc), a redox enzyme that 
triggers mitochondrial apoptosis, is implicated in the pathophysiology of aging and 
cardiovascular disease (18-20). Studies in experimental models suggest modulation of p66Shc 
expression and activity may be a novel and effective target for the treatment of cardiovascular 
complications. For instance, abrogation of p66Shc results in protection from angiotensin II-
induced cardiomyocyte damage (21), improvement of neovascularization and muscle fibres 
survival following induction of limb ischemia, and preservation of proliferation and 
differentiation of satellite cells exposed to high oxidative stress (22; 23). Upstream 
modulators of the p66Shc signaling pathways, such as the protein kinase C, isoform beta-II 
(PKCβII), which activates p66Shc through phosphorylation of its serine 36 residue at the C-
terminal moiety, also represents an attractive therapeutic target to halt ischemic complications 
(20; 24). Following successful use in diabetic animals, the PKCβII inhibitor LY333531, also 
known as Ruboxistaurin, has recently shown clear therapeutic benefit in clinical trials of 
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diabetic microvascular complications (25; 26). However, whether PKCβII inhibitors exert 
positive effects on myogenic stem cells from diabetic patients with vasculopathy remains 
currently unknown. 
The present study investigates molecular therapeutic targets to improve 
angiomyogenesis in patients with complicated diabetes. We assessed functional and 
molecular features of MPs harvested at the rim of tissue above the plane of limb amputation, 
which is a rescuable area similar to the peri-infarct border zone. We show for the first time 
that diabetic MPs (D-MPs) are dysfunctional in many respects. They have reduced capacity 
to expand in culture, differentiate into multinucleated myotubes and support endothelial cells 
(ECs) network formation.  Furthermore, an increased oxidative stress is recurrent in D-MPs, 
due to the down-regulation of superoxide dismutase 1 (SOD-1) and catalase and up-
regulation and activation of p66Shc. Importantly, blockade of p66Shc phosphorylation by 
PKCβII inhibition restores D-MPs functionality, providing a novel indication for molecular 
treatment of the angiomyogenic pathology in patients with diabetes. 
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METHODS 
 
Human studies 
Skeletal muscle biopsies were obtained from control and diabetic patients following informed 
consent in line with the guidelines of the Helsinki declaration on human rights. MPs were 
isolated from: 1) different anatomic districts of the lower extremities from control subjects 
referring to our Institutions for investigations/therapeutic interventions related to leg 
varicosity or suspected bone-related pathologies that then resulted negative (n=14) or 2) from 
sartorius muscles from type-2 diabetic patients at the occasion of major amputation for CLI 
(n=18). CLI was diagnosed according to TASC 2007, i.e. rest pain and/or ulcer or gangrene, 
transcutaneous oximetry at the dorsum of the foot <30 mmHg and/or ankle pressure <70 
mmHg. Patients’ characteristics are listed in Table 1. We attempted performing all the 
analyses on the same sample. When this was not possible due to the small size of the 
harvested tissue, priority was given to histological analyses and then to the proliferation 
assay. Online Supplemental Table 1 summarizes samples attribution to different assays. 
 
Muscle immuno-histochemistry 
Morphometric analysis was performed on Haematoxylin & Eosin stained sections. For 
capillary analysis, sections were boiled in sodium citrate buffer pH 6.0, incubated with mouse 
monoclonal anti-CD31 antibody clone CJ70A (1:200, Dako), then washed and incubated with 
secondary antibody followed by DAB+ substrate 1:50 (Kit Dako REAL EnVision). Analysis 
of inflammatory infiltrates employed rabbit monoclonal anti-CD3 (clone 2GV6) and mouse 
monoclonal anti-CD68 (clone PG-M1) antibodies (both from Ventana). To localize MPs 
within the muscle structure, cryosections were treated with Alkaline Phosphatase (ALP) 
staining solution containing nitro-blue tetrazolium chloride (160ug/mL) and 5-bromo-4-
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chloro-3'-indolyphosphate p-toluidine salt (300ug/mL; both from Sigma-Aldrich) in ALP 
buffer (100mM TrisHCl, 150mM NaCl, 1mM MgCl2 pH 9.0). The same solution was used to 
stain isolated cells previously fixed in 2% formalin. ALP quantification in cryosections was 
carried out using Cell Profiler open source software distributed under GPLv2 public license. 
 
Myofibres Cross-Sectional Analysis 
Cryosections from diabetic and control muscle biopsies were stained with anti-laminin 
antibody and analyzed using an ImageJ macro. For each sample (n=3), the area of more than 
two thousand single fibres was measured. 
 
MP isolation 
Human MPs were isolated following well-established procedures (12; 27). Briefly, muscle 
biopsies were finely minced and digested with collagenase II (100U/mL) for 45min at 37°C 
on shaking. The digestion mixture was centrifuged and re-suspended in growth medium (α-
MEM supplemented with 20% FBS). The cell suspension was filtered through a 70μm cell 
strainer, dispensed in plastic dishes at clonal density (1000 cell/cm2) and incubated at 37°C 
and 5% CO2 in the growth medium. MPs were selected by plastic adherence in culture for at 
least 10 days when they form colonies positive for ALP, NG2 and CD146 (27).  
 
Transmission electron microscopy (TEM) 
For ultrastructural analysis, a pellet of MPs was fixed for 2h at 4°C in a mixture of 2% 
paraformaldehyde and 2% glutaraldehyde in 0.05mol/L pH7.3 cacodylate buffer, post-fixed 
in 1% osmium tetroxide, and embedded in Epon-Araldite. Thin sections were counterstained 
with uranyl acetate and lead citrate and examined with a Philips/FEI Morgagni electron 
microscope. 
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Immuno-cytochemistry 
After fixation with 4% paraformaldehyde, cells were permeabilized with 0.3% Triton X-100 
in PBS 1X + 1% BSA, then blocked with goat serum 10% in PBS 1X and incubated with 
polyclonal rabbit anti-NG2 (Merk Millipore), mouse monoclonal anti-CD146 (clone OJ79c, 
Abcam), mouse monoclonal anti-desmin (clone D33, Dako), mouse monoclonal anti-MyHC 
(clone MF20, DSHB), mouse monoclonal anti- Ser36-phospho-p66Shc (clone 6E10, Abcam), 
diluted following manufacturer’s instructions. Cells were further incubated with goat anti-
mouse or anti-rabbit fluorescent secondary antibodies (Alexa Fluor 488 or 555, Life 
Technologies). Nuclei were counterstained with DAPI (PanreacAppliChem). 
Microphotographs were acquired using the imaging software AxioVision Imaging System 
(Zeiss). When required for 3D image acquisition, an Olympus FV 1000 confocal laser 
scanning microscope with 60X oil immersion lens was used. 
 
MP flow cytometry 
MPs were stained for surface antigen expression using the following antibodies: CD44-APC, 
CD90-APC, and ALP-PerCP Cy5.5 (all from BD Biosciences). For Ser36-phospho-p66Shc 
quantification, cells were fixed and permeabilized using BD Citofix/Citoperm kit (BD 
Biosciences). They were then incubated with anti-Ser36-phospho-p66Shc (Abcam), followed 
by Alexafluor 633 conjugated secondary antibody. Fluorescence was analyzed on a 
FACSCanto flow cytometer using the FACSDiva software (BD Biosciences) setting a non-
labelled population as a negative control. 
 
Myogenic differentiation 
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MPs were seeded at 105 cells/well in 2-well glass chamber slides and expanded in culture for 
7 days to allow cell fusion and myotube formation. Cells were fixed with 4% PFA and 
permeabilized with 0.3% Triton X-100 1% BSA. Myogenic differentiation and myotube 
formation were assessed by staining cells with anti-myosin heavy chain antibody (MyHC, 
clone MF20, DSHB), followed by Alexafluor-555 conjugated secondary antibody. 
 
Adipogenic differentiation 
MPs were induced to differentiate into adipocytes using an inductive medium for 4 days, i.e. 
DMEM GlutaMAX high-glucose, 1% penicillin and streptomycin, 1% Sodium Pyruvate 
supplemented with 20% FBS, and insulin (1µg/mL). Adipogenic differentiation was assessed 
by Oil Red staining (Sigma-Aldrich) following PFA fixation. 
 
Proliferation assay 
MP proliferation was assessed by ELISA BrdU colorimetric assay kit (Roche). Briefly, cells 
(103 cells/well in a 96-well microplate in triplicate) were grown for 24h and then treated with 
BrdU (10μM final concentration) for additional 24h. The colorimetric reaction was stopped 
by adding H2SO4 (250mmol/L final concentration) and read immediately at 450 nm. 
 
EC network assay 
Human Umbilical Vein ECs (HUVECs) and MPs were seeded in an 8-well permanox 
chamber slide (Nunc, USA) coated with Matrigel (3D; BD Biosciences) alone (3.75x104 
cell/well) or co-cultured at 1:4 ratio (MPs to HUVECs) in EBM medium, supplemented with 
0.1% BSA. Cells were incubated for 5h post-seeding to allow network formation. Pictures of 
the network were taken on an inverted phase-contrast microscope (AxioObserverA, Zeiss, 
Germany) and network formation was assessed by counting the number of branches per field. 
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Similar angiogenesis assays were carried out to assess the effect of MP-derived paracrine 
factors, by adding Conditioned Culture Media (CCMs) to HUVECs seeded onto Matrigel. In 
a subset of these studies, the influence of MPs-CCM on in vitro angiogenesis was assessed in 
the presence of high oxidative stress, by adding 300µmol/L H2O2 to the media. All 
experiments were performed in duplicate. 
 
ELISA of MPs-CCM 
Levels of VEGF-A, IGF-1, MCP-1, SPARC, HGF, FGF and Ang-2 in MPs-CCM were 
measured by enzyme-linked immunosorbent assay (ELISA) using Duo Set kits (R&D/Bio-
Techne). Levels of Ang-1 were analyzed using the human angiopoietin-1 ELISA kit (Sigma-
Aldrich). All analyses were performed following the manufacturer’s instructions in triplicate 
(25ul of sample per replicate). 
 
Studies of MPs-derived exosomes  
Exosomes were isolated by sequential ultracentrifugation from MPs-CCM collected after 40h 
growth in a medium added with 20% exosome–free FBS as previously described (28; 29). 
Exosome-like microparticle abundance was revealed through Nano Tracking Analysis 
(NTA), and aliquots of the same preparation were added to HUVECs in the Matrigel assay. 
 
HUVEC redox state 
HUVEC intracellular redox state following treatment with MPs-CCM was investigated by 
using a lentiviral vector encoding for the redox-sensing green fluorescent protein (roGFP), 
which reports the GSH/GSSG balance (30). After overnight treatment of HUVECs with MPs-
CCM, H2O2 (100 and 300µmol/L) was added. Fluorescence measurements were performed in 
clear 24-well plates (Corning, Lowell, MA) on a fluorescence plate reader GENios plus 
  10 
(Tecan, Männedorf, CH) using a 535nm emission filter. The degree of oxidation of the 
roGFP was estimated from the ratios of light intensities obtained during 1min intervals under 
400 and 485nm excitation. 
 
ROS analysis 
ROS production by MPs was evaluated labeling cells with MitoSox (Invitrogen) according to 
the manufacturer’s instructions. Briefly, semi-confluent MPs were treated for 10min with 
5µmol/L MitoSox dye in culture. Fluorescence was analyzed using FACSCanto flow 
cytometer and the FACSDiva software (BD Biosciences). In inhibitory studies, the scavenger 
N-acetyl-cysteine (NAC 1mmol/L, Sigma-Aldrich) was added to MPs to infer the impact of 
ROS on MPs functions 
 
PKCβII inhibition 
Functional assays were performed on MPs treated with the PKCβII inhibitors LY333531 
(200nmol/L) or CGP53353 (2µmol/L) or vehicle. Pharmacological inhibition was extended 
for 7 days in the myogenic differentiation assays and 24h in the proliferation and 
angiogenesis assays. 
 
Gene expression analysis 
RNA was extracted using miRNAeasy extraction kit (Qiagen) according to the 
manufacturer’s instructions. cDNA was synthesized using TaqMan Reverse Transcription kit 
and then analyzed by QuantStudio™ 6 Flex Real-Time PCR System, normalizing the data to 
the 18S ribosomal RNA (18S rRNA). Primers for the CH2 domain of the p66 isoform were 
designed as follows: 
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5’GATCCCGAATGAGTCTCTGTCATCGTTGATATCCGCGATGACAGAGACTCATTC
TTTTTTCCAAA-3’  
and 
3’GGCTTACTCAGAGACAGTAGCAACTATAGGCGCTCTGTCTCTGAGTAAGAAAA
AAGGTTTTCGA-5’ 
 
Western Blot 
Cells were harvested after overnight serum starvation in lysis buffer (TRIS-HCl 20mmol/L, 
NaCl 150mmol/L, EDTA1mmol/L, EGTA1mmol/L, Triton X-100 1%) supplemented with 
1X COMPLETE protease inhibitor cocktail (Roche), 1X phosphatase inhibitor cocktail type 
II and III (Sigma-Aldrich) and 1X Benzonase (Novagen). Twenty-five micrograms of total 
cell lysates were loaded onto a NuPAGE 10% Bis-Tris precast gel (Life Technologies). 
Proteins were then transferred onto an Amersham Hybond PVDF membrane (GE Healthcare, 
0.45µm). Blocked membranes with 5% skim milk in 0.1% PBS-TWEEN20 were decorated 
with mouse monoclonal primary antibodies diluted according to the manufacturer’s 
instructions. Membranes were subsequently incubated with HRP conjugated anti-mouse 
secondary antibody (1:1000 in 5% skim milk in 0.1% PBS-TWEEN20). Bands were revealed 
using the C-Digit blot scanner (LI-COR Biosciences). 
 
Statistical analysis 
Continuous variables were expressed as mean±standard error (SEM) and compared using 
parametric tests (t-test and ANOVA) unless not normally distributed. A p-value <0.05 was 
considered statistically significant. The GraphPad Prism 5 software package was used for 
these analyses. 
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RESULTS 
Negative impact of diabetes on muscle anatomy and pericyte abundance 
A comparative analysis of muscle specimens from control and diabetic patients was carried 
out to assess myofibres organization and vascular cell structure. As illustrated in Figure 1A, 
left panel, muscle sections from diabetic patients show abundant and enlarged adipocytes 
(black star) and myofibres featuring degeneration (arrow) and nuclear centralization 
(arrowhead). Also, the average myofibre cross-section area was shifted to lower values in the 
diabetic samples compared with controls (Figure 1A, right panel). Moreover, we observed 
an inflammatory infiltrate in diabetic samples as evidenced by the abundance of CD3-positive 
lymphocytes and particularly CD68-positive macrophages (Figure 1B), which is in line with 
a previous investigation of ischemic muscles (31). Additionally, the count of CD31-positive 
capillaries revealed a significant decrease in muscle vascularization (Figure 1C). 
MPs embracing CD31-positive capillary ECs were identified by 
immunocytochemistry for NG2 (Figure 1D) and ALP (Figure 1D, Supplementary Figures 
S1A and B). An unbiased profiler analysis carried out using the Cell Profiler software (32), 
indicates a remarkable reduction in the density of ALP-positive MPs in diabetic muscles 
(Figure 1D lower panel).  
 
Diabetic MPs show ultrastructural alterations but maintain typical antigenic markers 
TEM analyses indicate ultrastructural alterations of D-MPs, consisting of blebbing and 
vacuolation (Figure 2A). Immunocytochemistry studies confirm the pericyte identity of 
freshly isolated cells, based on the expression of ALP, CD146, and NG2 (Figure 2B and C). 
Expanded MPs express the same markers while being negative for the satellite cell marker 
PAX7 (Figure 2D). Moreover, expanded MPs co-express NG2 and ALP (Figure 2E). Flow 
cytometry analyses indicate the statement of mesenchymal markers CD44 and CD90 (Figure 
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2F). MPs from control or diabetic patients did not differ from each other about antigen 
expression except desmin, which was down-regulated in D-MPs (Supplementary Figure 
S2A-C). 
 
Diabetic MPs display angiomyogenic deficits 
High confluence MPs differentiate and fuse forming myosin heavy chain (MyHC)-positive 
syncytial myotubes (33; 34). As shown in Figure 3A, D-MPs have reduced capacity to 
generate MyHC-positive myotubes as compared to control MPs (C-MPs), which may be 
ascribed in part to decreased proliferation, resulting in delayed cell confluence (Figure 3B). 
Additionally, we found that D-MPs have an increased propensity to differentiate into 
adipocytes (1.7±0.8 fold increase compared with C-MPs, n=3, Supplementary Figure S2D). 
In contrast, diabetes did not affect apoptosis, as assessed by caspase activity (6.7±2.2 vs. 
7.3±2.4 RFU at 499/521 nm in controls) or cell motility in a scratch assay at both 5h (8.7±3.7 
vs. 3.6±1.7 % wound closure in controls) and 24h post-scratch (60.0±13.8 vs. 43.4±17.4% in 
controls). 
We next analyzed the ability of MPs to form networks on Matrigel. Both C-MPs and 
D-MPs were able to form branched structures. In comparison with networks formed by 
HUVECs, the MPs structures consisted of longer tubes and wider meshwork (Figure 3C). 
When co-cultured with HUVECs, MPs locate near the intersection points or around the 
endothelial tubes (Figure 3D, white arrow and arrowhead). Importantly, D-MPs have 
detrimental effects on network formation, resulting in a less reticulated system (Figure 3E).  
 
Paracrine deficits of diabetic MPs 
To investigate if paracrine mechanisms are responsible for the negative impact of D-MPs on 
angiogenesis, we next tested the effect of MPs-conditioned media (MPs-CCM) on HUVECs 
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in the Matrigel assay. As shown in Figure 4A, the D-MPs-CCM induces a decrease in 
network formation, suggesting and alteration of the secretome. To verify this possibility, we 
interrogated secreted angiogenic myokines. ELISA showed significantly decreased levels of 
pro-angiogenic factors, i.e. VEGF-A, IGF-1, and Ang-1, in D-MPs-CCM (Figure 4B).  
Specific micro-RNAs (miRs) have recently been shown to regulate angiogenesis and 
their deregulation may contribute to vascular complications and ischemia (29; 35-37). Data 
from PCR analysis did not show any difference in the expression of classical angiomiRs, 
miR-16, miR-503 and miR-27b, between D-MPs and C-MPs (Supplementary Figure S3A). 
Also, the analysis of CCMs confirmed D-MPs and C-MPs secrete similar amounts of miR-
16, while miR-503 and miR-27b were undetectable (data not shown). Likewise, no 
difference was observed in the expression of the miR-27b targets thrombospondin-1 (TSP-1), 
sprouty-2 (SPRY-2) and semaphorin 6A (SEM6A) (Supplementary Figure S3A-ii and B), 
which are negative modulators of angiogenesis (36). 
Secreted exosomes mediate the functional cross-talk between pericytes and ECs (29; 
37; 38). Therefore, we next investigated if diabetes impacts on the MPs capacity to release 
exosomes or modifies exosomes activity on angiogenesis. Results indicate no difference in 
exosome-size vesicles shed by C-MPs and D-MPs (7.4±2.5x10-4 vs. 6.9±2x10-4 exosome 
concentration/cells, respectively). Also, the addition of exosomes from D-MPs to HUVECs in 
a Matrigel assay does not alter the network formation (10.7±1.9 vs. 10.8±0.4 
intersections/field in HUVECs+C-MPs), while exosome-depleted D-MPs-CCM still inhibits 
the process (data not shown).  
We next investigated the role of ROS as paracrine mediators of the negative cross-talk 
between D-MPs and ECs. To this end, HUVECs were transduced with lentiviral vectors 
carrying the cytosolic or the mitochondrial isoforms of roGFP, which act as fluorescent 
indicators of the intracellular redox status, (30) and were then incubated with C-MPs CCM or 
  15 
D-MPs CCM, before being exposed to increasing doses of the pro-oxidant H2O2. We found 
that C-MPs-CCM protects HUVECs from the pro-oxidant action of H2O2, whereas D-MPs-
CCM does not (Figure 4C). In additional experiments, we test if ROS per se impairs 
angiogenesis in vitro. To this end, HUVECs were exposed to a fixed dose of H2O2 
(300µmol/L) before being seeded into the Matrigel assay. As expected, H2O2 inhibited the 
HUVEC network formation capacity in a way comparable to the inhibition caused by D-MPs 
or their CCM. Interestingly, the addition of C-MPs-CCM contrasted the inhibitory effect of 
H2O2 on network formation, whereas the D-MPs-CCM was ineffective (Figure 4D). 
 
ROS blockade reverts functional deficits of diabetic MPs  
We next investigated the redox status of C-MPs and D-MPs by staining cells with MitoSox, a 
dye that selectively reacts with superoxide anion O2
• in mitochondria. Results of flow 
cytometry analyses indicate that D-MPs have remarkably increased oxidative stress levels as 
compared with C-MPs, either considering the average MitoSox dye intensity or number of 
MitoSox-positive cells (Figure 5A). Moreover, the ROS scavenger system involved in the 
maintenance of cellular redox balance was depressed, as indicated by the down-regulation of 
SOD-1 and catalase (Figure 5B). To confirm that the ROS imbalance contributes to D-MPs 
dysfunctions, we investigated if the addition of NAC, a generic antioxidant, restores inherent 
and paracrine activities of the diabetic cells. In line, NAC partially amended D-MPs 
myogenic differentiation capacity (Figure 6A), restored D-MPs proliferation (Figure 6B), 
and abrogated the inhibitory effect of D-MPs-CCM on HUVECs network formation in vitro 
(Figure 6C). Since the excess of ROS activates the p66Shc signaling pathway by its selective 
phosphorylation, the next step was to compare the levels and phosphorylation state of this 
protein in C-MPs and D-MPs. 
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Implication of p66Shc in the redox imbalance of D-MPs 
Using primers specifically designed for the p66 isoform of Shc1 protein, we found that p66Shc 
mRNA expression is significantly up-regulated in D-MPs as compared with C-MPs (Figure 
7A). Under unbalanced redox conditions, p66Shc is phosphorylated at the Ser36 of its unique 
CH2 domain and translocates to the mitochondrial transmembrane space, where it fuels 
additional ROS production, causing the formation of a permeability-transition pore and 
apoptosis. We analyzed the phosphorylation state of p66Shc in MPs by different methods. 
Using a specific western blot Ser36-p-p66Shc antibody, we observed an increase in the band 
of activated p66Shc with no difference in the total protein content (Figure 7B). Flow 
cytometry (Figure 7C) and immunocytochemistry (Figure 7D) confirmed the increased 
statement of phospho-p66Shc in D-MPs. Nonetheless, treatment of D-MPs with NAC was 
ineffective in restoring p66Shc phosphorylation to control levels (Supplementary Figure S4A 
and B). This result has different keys of interpretation. First, the thiol groups of the NAC 
molecule may undergo auto-oxidation processes especially in culture, which reduces their 
activity. Thus, a possible explanation is that NAC did not reach biologically relevant 
concentrations in mitochondria, where active p66Shc accumulates. Alternatively, p66Shc 
activation by PKCβII may be partially independent of ROS or resistant to temporary ROS 
reduction. The latter possibility is compatible with a reported epigenetic activation of the 
p66Shc promoter in the context of diabetes (39). Also, ROS scavenging by NAC may be 
insufficient to contrast the activity of protein kinases responsible for p66Shc phosphorylation, 
namely protein kinase C βII (PKCβII) (40). Accordingly, we found that NAC 
supplementation does not affect PKCβII localization or expression (Supplementary Figure 
S4C and D).  
 
Suppression of p66Shc activity by PKCβII inhibition reverts functional deficits of D-MPs 
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To assess the direct involvement of p66Shc in D-MPs dysfunction, p66Shc activation was 
blocked by interfering with its phosphorylation. To this purpose, we inhibited the PKCβII 
kinase, which is responsible for p66Shc activation (39). Two compounds were used to inhibit 
PKCβII in D-MPs: LY333531, also known as Ruboxistaurin already tested for therapeutic 
efficacy in clinical trials of diabetic retinopathy, and CGP53353.(41) Flow cytometry 
confirmed that both LY333531 and CGP53353 reduce the levels of Ser36-phospho-p66Shc 
(Figure 8A). We next re-assessed the features of D-MPs dysfunction following treatment 
with PKCβII inhibitors. Results indicate an overall functional improvement upon PKCβII 
inhibition, including myogenic differentiation (Figure 8B), proliferation (Figure 8C) and 
interference with network formation (Figure 8D) Those data indicate that blocking the 
PKCβII- p66Shc pathway may have important therapeutic implications for total restoration of 
D-MPs functions. 
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DISCUSSION 
The present study is the first to investigate the anatomical, functional and molecular diversity 
of MPs from skeletal muscles of diabetic patients with CLI. Importantly, MPs were isolated 
from the tissue immediately at the rim of normal tissue surrounding the plane of dissection, a 
critical zone where it is mandatory to concentrate efforts for limb salvage. Results show for 
the first time specific alterations consisting of ultrastructural modifications, proliferative 
impairment leading to blunted myogenic potential, and acquisition of an anti-angiogenic 
activity. Altogether, these deficits could contribute to the extension and severity of peripheral 
complications. Importantly, we discovered that diabetes-associated MPs incompetence is 
attributable to increased ROS levels, weakened anti-oxidative protection, and activated 
PKCβII-p66Shc signaling pathway. Also, excessive ROS production and release transmit 
negative signals to adjacent vascular cells. Muscle regeneration via trans-differentiation of 
MPs and satellite cells into myoblasts is crucial for the recovery of damaged muscles, 
whereas overgrowth of adipogenic cells may be deleterious. Some studies suggest that a 
subset of MPs contribute to fat accumulation (42). Our investigation shows structural data 
that are compatible with a differentiation bias of MPs favoring adipogenesis at detriment of 
myogenesis. Concurrent mechanisms may participate in this adverse remodeling, including 
poor metabolic control, ischemia, and lack of exercise (43). 
Unraveling the molecular mechanisms underpinning MPs dysfunction could help 
develop new strategies to maintain tissue integrity and improve clinical outcomes especially 
after major limb amputation, a condition associated with high mortality. Current mechanistic 
understanding of diabetic vasculopathy is mainly inferred from animal models (44). 
However, the clinical transferability of data from rodents mimicking human diabetes/CLI is 
limited and often equivocal. Therefore, the successful isolation of MPs from muscles of 
diabetic patients undergoing major limb amputation for CLI discloses excellent opportunities 
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for disease modeling and therapeutics. Since there is a potential overlapping between MPs 
and satellite cells, it was essential to ascertain that isolated cells express high levels of the 
canonical pericyte marker NG2 and ALP along with mesenchymal markers (CD90 and 
CD44), the staminal marker CD146, while being negative for PAX7. In fact, ALP positivity 
and PAX7 negativity are determinants to distinguish pericytes from ALP-/PAX7- mature 
myocytes or ALP-/PAX7+ satellite cells. When grown to over-confluence, MPs 
spontaneously fuse together to form syncytial myotubes expressing MyHC. Interestingly, the 
ability to form syncytial myotubes was drastically reduced in D-MPs, and this could be one 
of the reasons (together with satellite cell dysfunction) of the aberrant tissue repair of diabetic 
skeletal muscles.  
Skeletal muscle physiology is maintained by mutual trophic influences between MPs, 
ECs and myocytes (45). However, this cross-talk is perversely modified by diabetes. The 
present investigation integrates results of our recent study showing that p75NTR expression 
in ECs exposed to high glucose activates the transcription of miR-503, which negatively 
affects pericyte function (37; 46). Here, we newly show that D-MPs exert a drastic reduction 
of ECs ability to form in vitro networks through an alteration in the secretion of angiogenic 
growth factors. Instead, screening of several classical angiomiRs or exosomes did not provide 
any supplementary clue.  
An additionally accountable mechanism emerged from studies of the MPs redox state 
and was confirmed by the recognition of a reduced scavenging capacity of D-MPs, consisting 
of down-regulation of SOD-1 and catalase gene expression. Accordingly, restoration of the 
physiologic redox state by NAC supplementation led to the correction or attenuation of D-
MPs dysfunctions. A more in-depth analysis of the original culprit directed us to recognize 
the intracellular stress sensor as p66Shc protein. Several lines of evidence support this 
possibility: (i) p66Shc is up-regulated at mRNA level and (ii) and hyper-phosphorylated at the 
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Ser36 residue, which corresponds to an activated pro-oxidant state of p66Shc. However, NAC 
administration did not revert p66Shc activation so other targets are needed to suppress p66Shc 
activation. Previous studies in animal models employed the abrogation or silencing of p66Shc 
to infer its pathophysiological importance. However, this approach has translational 
limitations as p66Shc is thought to have bivalent actions (47). Thus, its total suppression may 
not be therapeutically desirable. Therefore, we decided to interfere with the excessive 
phosphorylation of p66Shc by inhibiting PKCβII (39; 41). Importantly, the use of PKCβII 
specific inhibitors, namely LY333531 or CGP53353, reverted p66Shc phosphorylation and 
restored D-MP functions. Even though NAC has been efficiently used to inhibit PKCβII 
expression in other experimental settings, dosages and cell type specificity may explain the 
observed differences (48; 49). Moreover, NAC is susceptible to auto-oxidation in culture 
conditions reducing its effectiveness. Importantly, PKCβII inhibitors lead, at least in vitro, to 
a more effective rescue of D-MPs myogenic differentiation capacity compared to NAC 
treatment, thus warranting additional investigation in patients with limb ischemia. This may 
be clinically relevant since generic antioxidant therapy has given disappointing results in 
trials assessing vitamins supplementation efficacy for cardiovascular diseases (50). 
In conclusion, we demonstrate that (i) MPs can be efficiently isolated from skeletal 
muscles of non-diabetic and diabetic patients; (ii) D-MPs are dysfunctional in terms of 
reduced myogenic ability, decreased proliferation and anti-angiogenic properties; (iii) those 
alterations are strictly related to an increased oxidative status driven by p66Shc over-
expression and activation; (iv) anti-oxidant treatment as well as p66Shc phosphorylation 
blockade by inhibition of PKCβII can rescue D-MP functional competence. 
These results are important since one of the used PKCβII inhibitors, LY333531, is 
currently at the final step of clinical trial investigation (phase 3) in patients with diabetic 
retinopathy. This opens invaluable opportunities for the treatment of life-threatening 
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complications of diabetes. We hypothesize that the use PKCβII inhibitors may halt the 
progression of CLI and allow surgeons to decide for less extensive amputations, when these 
become necessary, ultimately improving the life quality and duration of patients with 
complicated diabetes. 
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TABLE 1: Characteristics of the study populations  
 
 
Controls 
(n=14) 
Diabetic 
(n=18) 
p-value 
AGE (years±SEM) 70±3 75±2 0.1 
SEX (male, %) 54 67 0.2 
Time renown diabetes (Years±SEM) 0 17.2±3.2 
 
HbA1c % Hb±SEM(mmol/mol±SEM) n.a. 7.4±0.5 (63.2±4.3) 
 
Glycemia (mmol/L±SEM) 5.4±0.4 8.8±1.6 0.02 
Creatinine (μmol/L±SEM) 91.3±11 132.4±35 0.9 
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FIGURES 
Figure 1. In situ characterization of MPs. A) Representative microphotographs of 
Hematoxylin & Eosin (H&E) stained sections of human muscles. The arrow indicates 
degenerated fibres, while the arrowhead points at a centralized nucleus. Fat deposition is 
indicated by the black star. Quantitative analysis depicted in the bar graph. Fibres 
composition was compared between C-MPs and D-MPs measuring the cross-sectional area 
(left panel). B) The presence of inflammatory cells infiltration was quantified by 
immunohistochemistry using anti-CD3 and CD68 antibodies to detect respectively 
lymphocytes and macrophages (arrowheads). Macrophages infiltration was significantly 
increased in D-MPs. *p<0.05 vs. controls, n=4. Scale bar 20 µm. C) Capillaries in the 
sections are indicated by brown CD31 positive staining (black arrows) used for the 
quantification expressed in the bar graph. Values expressed as mean±SEM of 3 control and 9 
diabetic subjects; **p<0.01 vs. controls. Scale bar 20µm. D) Within the muscle structure, 
pericytes, which encircle capillaries (CD31 positive cells), were identified by NG2 
expression (white arrowheads). Nuclei were counterstained with DAPI. Pericyte count in bar 
graph. *p<0.05 vs. control. Scale bar 20µm. In addition, pericytes were identified by 
positivity for ALP using the Cell Profiler software. The number of ALP-positive pericytes in 
muscles from diabetic patients was significantly reduced with respect to controls. Values 
expressed as mean±SEM on 3 different donors; * p<0.05 vs. controls. Scale bar 100 µm. 
 
Figure 2. Characterization of isolated MPs. A) Transmission electron microscopy 
ultrastructure of MPs. Magnification: 7100X. B) ALP immunostaining and C) NG2 and 
CD146 immunofluorescence of MPs after isolation from muscle biopsies. Positive cells were 
purple stained. Scale bar 20µm. D) MPs expression of ALP, NG2, CD-146 and PAX7 to 
assess the antigenic characteristics of isolated cells. Nuclei were counterstained with DAPI. 
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Scale bar 50μm. E) Double staining of MPs with ALP and anti NG2. Scale bar 10μm. F) 
Flow cytometry analysis of MPs. Data showed as peaks of positivity to the staining (red line) 
for the markers CD90, CD44 and ALP vs. negative control (dark line). 
 
Figure 3. MP differentiation, proliferation and network formation. A) Muscle 
differentiation: MPs were stained with anti-myosin heavy chain (MyHC) antibody to reveal 
syncytial myofibre-like structures (yellow arrowheads) generated by fusion. Nuclei were 
counterstained with DAPI. Bar graph summarizes the number of MyHC positive fibres 
counted on the total number of nuclei per field. Counts were made on 5 pictures from at least 
3 biological replicates. Picture magnification 20X, scale bar 50μm. Values expressed as 
mean±SEM. *p<0.05 vs. C-MPs. B) Cell proliferation was measured as optical density after 
48h of culture of which the last 24h in the presence of 5-bromo-2'-deoxyuridine (BrdU) as 
described in “Methods”. Values are expressed as mean±SEM of 4 experiments in triplicate. 
*p<0.05 vs. C-MPs. C) Matrigel assay: compared to HUVECs (left panel), MPs (right panel) 
form networks less reticulated with thicker nodes and longer tubes. Scale bar 100 µm. D) 
HUVECs-MPs interaction on Matrigel. Fluorescent microphotograph of networks formed on 
Matrigel by co-culturing HUVECs (stained red with PKH26 dye) and MPs (stained green 
with PKH67 dye) at 5x magnification. MPs locate preferentially at nodes of the network 
(white arrow). They are also located along the tube assisting HUVECs in tubulization (white 
arrowhead). Scale bar 100µm. E) Direct interaction with endothelial cells (HUVECs): 
microphotographs of networks formed by MPs in co-culture with HUVECs at a 1:4 
MPs/HUVECs ratio. Bar graphs represent the efficiency of network formation in terms of 
number of branches. Values expressed as mean±SEM of at least 5 experiments in duplicate; 
*p<0.05 vs. HUVECs+C-MPs. Scale bar 100 μm.  
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Figure 4. Paracrine effect of MPs on HUVECs. A) Matrigel assay performed with 
HUVECs at 5x104 cell density in the presence of MPs-CCM. Bar graphs represent the 
efficiency of network formation (number of branches). Values expressed as mean±SEM of 5 
experiments in duplicates. *p<0.05 vs. HUVECs+C-MPs-CCM. Scale bar 100μm. B) 
Myokines regulating angiogenesis were analyzed by ELISA in MPs-CCM. *p<0.05 vs. C-
MPs; **p<0.01 vs. C-MPs in at least 3 samples. Data is represented as the average of each 
condition (control vs. diabetic) with a standard error of the mean. C) roGFP-expressing 
HUVECs were used as a tool to analyze the HUVEC susceptibility to oxidative stress. Values 
expressed as mean fluorescence ± SEM of 3 experiments in quadruplicates. *p<0.05 and 
**p<0.01 vs. C-MPs-CCM. D) HUVECs were treated during network formation with 
300µmol/L H2O2 to test the effect of oxidative stress. MPs-CCM were also supplemented 
with 300 µmol/L H2O2 and added to HUVECs. Network formation was quantified as number 
of branches. Values expressed as mean±SEM of 4nexperiments in duplicates. *p<0.05 vs. 
HUVECs. Scale bar 100 μm. 
 
Figure 5. Analysis of pericyte redox status. A) MPs were stained with 5 µmol/L MitoSox 
and read on a FACSCantoII flow cytometer in the PE channel. Data quantified in the bar 
graph. Values expressed as mean±SEM of percentages of positive populations. Sample size 
n=4, *p<0.05 vs. C-MPs. B) Transcriptional analysis of the antioxidant genes SOD-1 and 
catalase. Values are expressed as mean±SEM of 5 experiments. *p<0.05 vs. C-MPs. 
 
Figure 6. NAC restores D-MPs functions. A) Myotube differentiation was evaluated by 
assessing MyHC-expressing cells. Quantification was performed counting the number of 
MyHC-expressing cells on the total cells here expressed as bar graphs. *p<0.05 vs. D-MPs in 
at least 4 samples. Scale bar 50μm. B) Cell proliferation measured by BrdU incorporation 
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assay following 30 min exposure to NAC (1 mmol/L) prior to BrdU addition. Values 
expressed as mean±SEM of 4 experiments in triplicate per group. *p<0.05 vs.C-MPs; 
#p<0.05 vs. D-MPs. C) Matrigel-assisted HUVEC network formation was analyzed following 
D-MPs treatment with NAC (1mmol/L for 30 min). Representative microphotographs and bar 
graphs show the efficiency of network formation as assessed by counting the number of 
branches. Values are expressed as mean±SEM of 3 experiments in duplicates. *p<0.05 vs: 
HUVECs, #p<0.05 vs. HUVECs+C-MPs and §.p<0.05 vs. HUVECs+D-MPs. Scale bar 
100μm. 
 
Figure 7. Induced p66Shc expression in D-MPs. A) Transcriptional analysis of the ROS 
sensor protein p66Shc. Values are expressed as mean±SEM of 3 experiments. *p<0.05 C-MPs. 
B) Western blot: C-MPs (lane 1) and D-MPs (lane 2) were compared for the expression of 
both total p66Shc and serine phosphorylated (Ser36-p-p66Shc) isoforms using anti-Ser36-p-
p66Shc-clone 6E10. C) Flow cytometry analysis and quantification of the percentage of 
Ser36-p-p66Shcpositive cells are expressed as mean±SEM of 3 experiments. *p<0.05 vs. C-
MPs. D) Immunofluorescence microscopy analysis of phospho-p66Shc positive MPs. Scale 
bar 50 μm. 
 
Figure 8. PKCβII inhibitors LY333531 and CGP53353 restore D-MPs functions 
counteracting p66Shc activation. A) The selective inhibition of kinase PKCβII responsible 
for the phosphorylation-mediated activation of p66Shc was achieved treating D-MPs with 
200nmol/L LY333531 or 2µmol/L CGP53353. Cell functions like myogenic differentiation 
(B), proliferation (C) and network formation on Matrigel (D) were all recovered following 
PKCβII inhibition-dependent p66Shc blockade. Values expressed as mean±SEM. *p<0.05 vs. 
D-MPs and **p<0.01 vs. D-MPs. For Matrigel assay *p<0.05 vs. HUVECs,#p<0.05 vs. 
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HUVEC+D-MPs and *p<0.05 vs. HUVECs+D-MPs, and n=3. Scale bar 50µm for myogenic 
differentiation pictures (20X magnification) and 100µm for Matrigel microphotographs (5X 
magnification). Sample size n=4. 
